ResMed's Q2 earnings beat expectations, driven by high demand for sleep products and digital health solutions.

From Nasdaq: 2025-01-30 19:44:26

ResMed (NYSE:RMD) exceeded expectations with strong Q2 2025 earnings, reporting an adjusted EPS of $2.43 and revenue of $1.282 billion, beating estimates. The company’s success was driven by high demand for sleep-related products and digital health solutions. ResMed’s revenue increased by 10.2% year over year, with the Sleep and Breathing Health segment reaching $1.13 billion in revenue. The company’s strategic focus on innovation and expansion into digital health technologies and new markets has contributed to its growth. Despite operational challenges like rising freight costs, ResMed remains optimistic about future opportunities for growth and market leadership.



Read more at Nasdaq: ResMed: Digital Health Drives Q2 Growth